BeOne Medicines (BEIGF) Other Non Operating Income (2015 - 2026)

BeOne Medicines (BEIGF) has reported Other Non Operating Income for 12 consecutive years, with -$749000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non Operating Income fell 109.17% year-over-year to -$749000.0 in Q2 2026; TTM through Jun 2026 was -$40.9 million, a 521.43% decrease from a year earlier, with the FY2025 full-year figure at -$42.6 million, down 236.71% from the prior year.
• Other Non Operating Income was -$749000.0 for Q2 2026 at BeOne Medicines, down from $14.5 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $336.7 million in Q3 2023 and troughed at -$129.6 million in Q2 2022.
• A 5-year average of $2.4 million and a median of $2.9 million in 2024 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 390.25% in 2022, down 14850.06% in 2022.
• Over 5 years, Other Non Operating Income stood at $19.4 million in 2022, then dropped by 13.83% to $16.7 million in 2023, then tumbled by 182.0% to -$13.7 million in 2024, then plunged by 159.87% to -$35.7 million in 2025, then surged by 97.9% to -$749000.0 in 2026.
• The last three Other Non Operating Income figures came in at -$749000.0 (Q2 2026), $14.5 million (Q1 2026), and -$35.7 million (Q4 2025), per Business Quant data.